1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients

ABSTRACT

Background: Cancer patients are at high risk of psychological problems and COVID-19 infection, which makes them even more vulnerable to mood disorders. Our objectives were to analyze the level of anxiety and depression among patients with advanced cancer during the COVID-19 pandemic and to analyze the association between sociodemographic, clinical, and psychological factors in patients with advanced cancer. Methods: A prospective, cross-sectional, multicenter study was conducted in 15 oncology departments in Spain. Patients with locally advanced unresectable or metastatic cancer who were candidates for systemic treatment were included. Patients completed demographic information and the Brief Symptom Inventory (BSI), Michel´s Uncertainty in Illness Scale (MUIS), Mental Adjustment to Cancer (MAC), and Cancer Worry Scale (CWS). Results: A total of 374 patients were recruited (April 2020-2021). The mean age was 64.2 years (34-88) and 48.7% were women. The most frequent were lung (30.7%) and colon (14.2%) cancers and most had metastases (78.6%). The most frequent therapy was chemotherapy (57.9%). The prevalence of anxiety and depression was 35% and 34%, respectively. Anxiety and depression levels were higher in women (p=0.001 and p=0.003, respectively). Patients <65 years (p=0.017) and with an oncologist-estimated survival of >18 months (p=0.033) had more anxiety symptoms. Logistic regression analysis revealed that women, patients with coping based on anxious preoccupation and hopelessness had higher risk of anxiety and depression (all, p<0.001). Conclusions: Patients with advanced cancer who start treatment during the COVID-19 pandemic experience high levels of depression and anxiety. Early diagnosis and the development of intervention strategies are needed especially in specific patient subgroups such as young women with long survival estimated times. Legal entity responsible for the study The authors. Funding: This work was funded by FSEOM (Spanish Society of Medical Oncology Foundation). Disclosure B. Obispo Financial Interests, Personal, Invited Speaker Lilly;Financial Interests, Personal, Invited Speaker Sanofi;Financial Interests, Personal, Invited Speaker Fresenius;Financial Interests, Personal, Invited Speaker Rovi. R. Hernandez Financial Interests, Personal, Advisory Role Amgen;Financial Interests, Personal, Invited Speaker Servier;Financial Interests, Personal, Invited Speaker Lilly;Financial Interests, Personal, Invited Speaker Roche;Financial Interests, Personal, Invited Speaker Merck;Financial Interests, Personal, Invited Speaker Ipsen. P. Cruz Financial Interests, Personal, Invited Speaker Bristol;Financial Interests, Personal, Advisory Board Boehringer Ingelheim. A. Fernandez Montes Financial Interests, Personal, Advisory Role BMS;Financial Interests, Personal, Advisory Role MSD;Financial Interests, Personal, Invited Speaker MSD;Financial Interests, Personal, Invited Speaker Servier;Financial Interests, Personal, Invited Speaker Lilly;Financial Interests, Personal, Advisory Role Lilly;Financial Interests, Personal, Advisory Role AstraZeneca;Financial Interests, Personal, Invited Speaker Pierre Fabre;Financial Interests, Personal, Invited Speaker Merck. N. Piera Molons Financial Interests, Personal, Invited Speaker Grunenthal;Financial Interests, Personal, Invited Speaker Kyowa Hakko Kirin;Financial Interests, Personal, Expert Testimony Ordesa. V. Pacheco-Barcia Financial Interests, Personal, Invited Speaker Eisai;Financial Interests, Personal, Invited Speaker Merck;Financial Interests, Personal, Invited Speaker Bristol-Myers Squibb;Financial Interests, Personal, Invited Speaker MSD;Financial Interests, Personal, Invited Speaker Leo Pharma;Financial Interests, Personal, Invited Speaker Kiowa Hakko Kyrin;Financial Interests, Personal, Invited Speaker Grunenthal;Financial Interests, Personal, Invited Speaker Prostakan;Financial Interests, Personal, Invited Speaker Lilly. M.H. López de Ceballos Financial Interests, Personal, Invited Speak r Roche;Financial Interests, Personal, Invited Speaker Eisai;Financial Interests, Personal, Invited Speaker Novartis;Financial Interests, Personal, Invited Speaker AstraZeneca. M. Antoñanzas Basa Financial Interests, Personal, Other, Personal fees AstraZeneca;Financial Interests, Personal, Other, Personal fees and no financial support Novartis;Financial Interests, Personal, Other, Personal fees Pierre Fabre;Financial Interests, Personal, Other, Personal fees and non-financial support MSD;Financial Interests, Personal, Other, Personal fees and non-financial support Sanofi;Financial Interests, Personal, Other, Personal fees Pfizer. D. Lorente Financial Interests, Personal, Invited Speaker, Advisory, travel fees Janssen;Financial Interests, Personal, Invited Speaker, Advisory, travel fees Sanofi;Financial Interests, Personal, Invited Speaker Bayer;Financial Interests, Personal, Invited Speaker, Advisory, travel fees Astellas;Financial Interests, Personal, Invited Speaker, Consultancy, travel fees BMS;Financial Interests, Personal, Invited Speaker, Advisory AstraZeneca;Financial Interests, Personal, Invited Speaker, Travel fees Pfizer. A. Manzano Fernández Financial Interests, Personal, Invited Speaker Roche;Financial Interests, Personal, Invited Speaker MSD;Financial Interests, Personal, Invited Speaker Leo Pharma;Financial Interests, Personal, Invited Speaker Sanofi;Financial Interests, Personal, Invited Speaker AstraZeneca;Financial Interests, Personal, Invited Speaker Rovi;Financial Interests, Personal, Invited Speaker Pharmamar;Financial Interests, Personal, Advisory Board Grunenthal;Financial Interests, Personal, Advisory Board AstraZeneca. S. Hernando Polo Financial Interests, Personal, Invited Speaker, Advisory role Pfizer;Financial Interests, Personal, Advisory Board GlaxoSmithKline;Financial Interests, Personal, Advisory Board Clovis;Financial Interests, Personal, Advisory Board Pharmamar;Financial Interests, Personal, Invited Speaker, Advisory role AstraZeneca. M. Gonzalez Moya Financial Interests, Personal, Invited Speaker Bristol;Financial Interests, Personal, Invited Speaker MSD;Financial Interests, Personal, Invited Speaker Sanofi;Financial Interests, Personal, Invited Speaker Boehringer Ingelheim;Financial Interests, Personal, Invited Speaker Roche;Financial Interests, Personal, Invited Speaker Merck. All other authors have declared no conflicts of interest.